肺癌免疫治疗进展PPT幻灯片.pptVIP

挑战：不同免疫治疗药物之间的联合应用 免疫治疗药物与化疗药物联合应用 免疫治疗与分子靶向治疗 免疫治疗与放疗联合应用 免疫治疗与局部治疗的应用 。。。。。。。 * Microsoft Engineering Excellence Microsoft Confidential * MED14736(Anti-PDL1) safety: No colitis, no high grade pneumonitis ,no drug-related deaths * Ongoing MEDI4736 (Anti-PDL-1)Clinical Trials in Patients With NSCLC Line of Therapy Phase PD-L1 Selection Comparator Single-agent MEDI4736 ≥ 2nd line[1] II Yes NA Post chemo-RT for IIIA NSCLC[2] II Yes NA Combination MEDI4736 NA[3,4] I No + tremelimumab ≥ 2nd line for EGFR+ NSCLC[5] I No + gefitinib NA[6] I No + MEDI0680 (PD-1) 1. ClinicalTrials.gov. NC 2. ClinicalTrials.gov. NC 3. ClinicalTrials.gov. NC 4. ClinicalTrials.gov. NC 5. ClinicalTrials.gov. NC 6. ClinicalTrials.gov. NC * NSCLC-other key PD-1/PD-L1 data presented at 2014 ASCO * Future Outlook Update of checkpoint Inhibitors in lung cancer therapy Cancer Immunotherapy 1 2 3 Outline * Tumor Chemo, Targeted, Hormone Therapy Rapid Activity, Tumor Shrinkage Targeting tumor and tumor microenvironment Targeting host immune system ? highly specific anti-tumor immunity ? memory: Durable response (cure?) Understanding of Tumor Biology Immunology Enables Rational Immuno-Combination * Effects of immunotherapy and targeted therapy on melanoma survival curves Clin Cancer Res. 2012;18:336-341. * Combining Immunotherapy and Conventional Therapies Yrs Immunotherapy Targeted Therapy Survival Combination Controls/ Conventional Therapy Clin Cancer Res. 2012;18:336-341. improve the survival? * Targeting tumor and tumor microenvironment Targeting host immune system ? highly specific anti-tumor immunity ? memory: Durable response (cure?) Tumor Chemo, Targeted, Hormone Therapy Rapid Activity, Tumor Shrinkage HOW? * THANK YOU ！谢谢！ * * * * * Cancer Immunotherapy 2013年是肿瘤治疗的一个转折点，在肿瘤的免疫治疗之路上经过长期不懈的执着追求终于